Trends in mortality in patients with systemic autoimmune rheumatic diseases (SARD) during the COVID-19 pandemic in Mexico
Authors:
- Pamela Munguía-RealpozoPMPamela Munguía-Realpozo
- Claudia Mendoza-PintoCMClaudia Mendoza-Pinto
- Ivet Etchegaray-MoralesIEIvet Etchegaray-Morales
- Juan Carlos Solis-PoblanoJSJuan Carlos Solis-Poblano
- Jorge Ayón-AguilarJAJorge Ayón-Aguilar
- Edith Ramírez-LaraEREdith Ramírez-Lara
- Jacsiry Orbe-SosaJOJacsiry Orbe-Sosa
- Socorro Méndez-MartínezSMSocorro Méndez-Martínez
- Mario García-CarrascoMGMario García-Carrasco
Open Access
- 22 June 2023
- journal article
- research article
- Published by Springer Nature in Rheumatology International
- Vol. 43 (9) , 1611-1619
Abstract
The study aimed to analyze the influence of the COVID-19 pandemic on mortality rates in patients with systemic autoimmune rheumatic diseases (SARD) in Mexico. We selected SARD-related deaths using National Open Data and Information from the Ministry of Health, Mexico, and ICD-10 codes. We assessed the observed compared to the predicted mortality values for 2020 and 2021, employing trends from 2010 to 2019 with joinpoint and prediction modelling analyses. Among 12,742 deaths due to SARD between 2010 and 2021, the age-standardized mortality rate (ASMR) increased significantly between 2010 and 2019 (pre-pandemic) (annual percentage change [APC] 1.1%; 95% CI 0.2–2.1), followed by a non-significant decrease during the pandemic period (APC 13.9%; 95% CI 13.9–5.3). In addition, the observed ASMR of 1.19 for 2020 for SARD and of 1.14 for 2021 were lower than the predicted values of 1.25 (95% CI 1.22–1.28) for 2020 and 1.25 (95% CI 1.20–1.30) for 2021. Similar findings were identified for specific SARD, mainly systemic lupus erythematosus (SLE), or by sex or age group. Interestingly, the observed mortality rates for SLE in the Southern region of 1.00 in 2020 and 1.01 in 2021 were both significantly greater than the predicted values of 0.71 (95% CI 0.65–0.77) in 2020 and 0.71 (95% CI 0.63–0.79). In Mexico, the observed SARD mortality rates were not higher than the expected values during the pandemic, except for SLE in the Southern region. No differences by sex or age group were identified.Keywords
This publication has 24 references indexed in Scilit:
- Impact of the COVID-19 Pandemic on the Appropriateness of Diagnostic Pathways of Autoimmune Rheumatic DiseasesThe Journal of Rheumatology, 2021
- Changing trends in rheumatoid arthritis mortality in Mexico, from 1998 to 2017Rheumatology International, 2021
- Heterogeneity in Excess Mortality and Its Impact on Loss of Life Expectancy due to COVID-19: Evidence from MexicoCanadian Studies in Population, 2021
- COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responsesThe Lancet Rheumatology, 2021
- Association of Race and Ethnicity With COVID‐19 Outcomes in Rheumatic Disease: Data From the COVID‐19 Global Rheumatology Alliance Physician RegistryArthritis & Rheumatology, 2021
- Concerns, Healthcare Use, and Treatment Interruptions in Patients With Common Autoimmune Rheumatic Diseases During the COVID-19 PandemicThe Journal of Rheumatology, 2020
- Systemic rheumatic diseases: From biological agents to small moleculesAutoimmunity Reviews, 2019
- Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosusSeminars in Arthritis and Rheumatism, 2017
- The importance of the type I interferon system in autoimmunity.2016
- Permutation tests for joinpoint regression with applications to cancer ratesStatistics in Medicine, 2000